braf - Robuta Search

https://www.brafscholarships.org/ BRAF Scholarships Scholarships offered by Baton Rouge Area Foundation donors braf scholarships https://boris-portal.unibe.ch/entities/publication/aef1cdbb-ee2f-414f-bc35-929fe1be6304 Structure-based prediction of BRAF mutation classes using machine-learning approaches. The BRAF kinase is attracting a lot of attention in oncology as alterations of its amino acid sequence can constitutively activate the MAP kinase signaling... machine learning structure based prediction braf https://www.mdpi.com/2072-6694/15/7/2117 Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic... Rechallenge with anti-EGFR drugs represents a promising strategy in refractory RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC). We performed the... https://open.library.emory.edu/concern/publications/f8075377-54eb-4b0f-8560-36c71281e024?locale=en Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation | OpenEmory Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation distinct features braf mutation https://adisinsight.springer.com/trials/700249223?error=cookies_not_supported&code=06b5491b-d422-4c20-81ae-9a166b525a3e Phase II Biomarker Study Evaluating The Upfront Combination Of BRAF Inhibitor Dabrafenib With MEK... This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the https://pubmed.ncbi.nlm.nih.gov/24982505/ High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis Langerhans cell histiocytosis (LCH) represents a clonal proliferation of Langerhans cells. BRAF V600E mutations have been identified in approximately 50% of... https://pubmed.ncbi.nlm.nih.gov/37999148/ Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation (1) Background: BRAF mutations affect 4-5% of lung adenocarcinomas. This study aimed to analyze the clinicopathological features of lung carcinomas with BRAF... small cell features non https://pubchem.ncbi.nlm.nih.gov/bioassay/1793982 AID 1793982 - KinomeScan assay: inhibition of BRAF(V600E) - PubChem BioAssay record AID 1793982 submitted by ChEMBL: KinomeScan assay: inhibition of BRAF(V600E). aid assay inhibition braf pubchem https://pubmed.ncbi.nlm.nih.gov/33260892/ BRAF: A Two-Faced Janus two faced braf janus https://our.utah.edu/urs/characterizing-the-interactome-of-braf-kinase-to-understand-its-oncogenic-mechanisms-in-the-development-and-progression-of-melanomas/ Characterizing the Interactome of BRAF Kinase to Understand its Oncogenic Mechanisms in the... https://pubmed.ncbi.nlm.nih.gov/35026411/ Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated... These updated results confirm the substantial clinical benefit and manageable toxicity of dabrafenib plus trametinib in BRAF V600E-mutant ATC. Dabrafenib plus... https://pubchem.ncbi.nlm.nih.gov/bioassay/1746919 AID 1746919 - Induction of apoptosis in human A375 cells expressing wild-type NRAS and BRAF V600E... BioAssay record AID 1746919 submitted by ChEMBL: Induction of apoptosis in human A375 cells expressing wild-type NRAS and BRAF V600E mutant at 1-3 uM relative... https://adisinsight.springer.com/trials/700243604?error=cookies_not_supported&code=3dec89cf-7c99-4b80-90f4-efee24589f9b A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600... This study was investigating the efficacy of encorafenib [LGX818] in patients with BRAF V600 mutant advanced or metastatic non small cell lung cancer. https://scholars.lib.ntu.edu.tw/entities/publication/71413361-9b0a-4c17-99fe-0a2cf7503d11 The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional... Anaplastic thyroid cancer (ATC) is a rare but lethal thyroid cancer. Dabrafenib and trametinib has been the standard treatment for the patients with BRAF... https://pmc.ncbi.nlm.nih.gov/articles/PMC9660367/ Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in... Thymosin beta-4 (TMSB4X) was recently identified as a differentially expressed gene between malignant and non-malignant thyroid cells via single-cell RNA... https://pubmed.ncbi.nlm.nih.gov/16024606/ Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers The BRAF V600E mutation has been associated with microsatellite instability and the CpG island methylator phenotype (CIMP) in colon cancer. We evaluated a... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1608538/full Frontiers | Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic... BackgroundBRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis and limited response to standard therapies. Recent clinical... https://publikationen.uni-tuebingen.de/xmlui/handle/10900/104151 Tolerability of BRAF/MEK inhibitor combinations : adverse event evaluation and management adverse event tolerability braf mek inhibitor https://blog.libero.it/wp/medicinanews/tag/tumore-del-polmone-b-con-mutazioni-braf-newsletter/ Tumore del polmone B con mutazioni BRAF Newsletter Archivi - Medicina News by Xagena tumore del polmone https://pubmed.ncbi.nlm.nih.gov/27388325/ Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in... Results observed in this case encourage further research on the activity of sorafenib in both HCC and NSCLC, based on the presence of BRAF mutation. This could... https://connect.mayoclinic.org/discussion/side-effects-from-braf-positive-targeted-therapy-drugs/ Side effects from BRAF positive targeted therapy drugs | Mayo Clinic Connect My husband, 78 y/o is a survivor of bladder cancer; thyroid cancer and lung cancer, now recurrent post surgical removal of left upper lobe of... side effects targeted therapy mayo clinic braf positive https://sciencedaily.com/releases/2025/01/250125152749.htm Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated... Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib... https://tobias-lib.uni-tuebingen.de/xmlui/handle/10900/125177?show=full Verteilung und Frequenz von BRAF Mutationen bei Patienten mit fortgeschrittenem Melanom in... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01682083 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive... Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). https://www.researchandmarkets.com/reports/6219866/braf-mutated-non-small-cell-lung-cancer BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast... BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036 small cell lung cancer https://pmc.ncbi.nlm.nih.gov/articles/PMC9563418/ TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience... TERT promoter mutation has recently emerged as a promising prognostic biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation.... https://www.gtue-braf.de/ Ingenieurbüro Ingar Braf - Home ingar braf https://pubmed.ncbi.nlm.nih.gov/36635469/ Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative... Erdheim-Chester disease (ECD) is a rare histiocytosis due to proto-oncogene mutations, primarily affecting the long bones and possibly being treated by novel... https://medlineplus.gov/lab-tests/braf-genetic-test/ BRAF Genetic Test: MedlinePlus Medical Test A BRAF genetic test looks for changes (mutations) in the BRAF gene. The results can guide treatment for melanoma and certain other cancers. Learn more. braf genetic test medlineplus medical https://pubmed.ncbi.nlm.nih.gov/26863566/ The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy... Metastatic melanoma (MM) is a highly aggressive cancer with a median overall survival of 6-9 months, notwithstanding the numerous efforts in development of new... the next generation https://pubmed.ncbi.nlm.nih.gov/22621641/ BRAF inhibition in refractory hairy-cell leukemia BRAF inhibition in refractory hairy-cell leukemia braf inhibition refractory hairy cell https://pubmed.ncbi.nlm.nih.gov/26314551/ The distribution of BRAF gene fusions in solid tumors and response to targeted therapy Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer... https://iris.cnr.it/handle/20.500.14243/459541 PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation mapk signaling braf translation https://pmc.ncbi.nlm.nih.gov/articles/PMC9338780/ Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated... Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on... https://eprints.ncl.ac.uk/247260 Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected... https://pubchem.ncbi.nlm.nih.gov/bioassay/1790934 AID 1790934 - BRAF Kinase screen - PubChem BioAssay record AID 1790934 submitted by ChEMBL: BRAF Kinase screen. aid braf kinase screen pubchem https://research.manchester.ac.uk/en/publications/analytical-validation-of-braf-mutation-testing-from-circulating-f/ Analytical validation of BRAF mutation testing from circulating free DNA using the amplification... https://en.wikipedia.org/wiki/BRAF_(gene) BRAF (gene) - Wikipedia braf gene wikipedia https://pubmed.ncbi.nlm.nih.gov/30831205/ Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung... BRAF fusion is a mechanism of AR to EGFR TKI therapy in approximately 2% of patients. Combined inhibition of EGFR and MEK (with osimertinib and trametinib) or... https://seguralab.duke.edu/publications/cutaneous-wound-healing-through-paradoxical-mapk-activation-by-braf-inhibitors/ Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors | Duke University -... Apr 22, 2021 - BRAF inhibitors are highly effective therapies for the treatment of BRAF(V600)-mutated melanoma, with the main toxicity being a variety of hyperproliferative... cutaneous wound healing https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00168/full Frontiers | Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive... Melanoma brain metastasis with ependymal spread/metastases is uncommon. These cases are frequently classified together with leptomeningeal disease. However... targeted therapy https://experts.umn.edu/en/publications/braf-and-nras-mutations-in-melanoma-and-melanocytic-nevi/ BRAF and NRAS mutations in melanoma and melanocytic nevi - Experts@Minnesota mutations in melanoma braf nras nevi experts https://iris.cnr.it/handle/20.500.14243/369244 BRAF(V600E)-mutant cancers display a variety of networks by SWIM analysis: prediction of... https://pubmed.ncbi.nlm.nih.gov/28368422/ Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma The melanoma incidence continues to increase, and the disease remains incurable for many due to its metastatic nature and high rate of therapeutic resistance.... abl kinase https://csn.cancer.org/discussion/215195/anyone-with-confirmed-kras-or-braf-mutations-trial-starting-at-unc-chapel-hill-now-plus-another-ite Anyone with confirmed KRAS or Braf mutations:trial starting at UNC-Chapel Hill now (plus another... if you are eligible for second line Tx for mets, tho of 240 people to be selected some it appears will be givena placebo (This I dislike) for something called... https://incubator.wikimedia.org/wiki/Wt/zea/braf?action=edit&redlink=1 Creating Wt/zea/braf - Wikimedia Incubator creating wt zea braf wikimedia https://iris.cnr.it/handle/20.500.14243/515491 Heterogeneous pathogenesis of melanoma: BRAF mutations and beyond heterogeneous pathogenesis melanoma braf mutations https://edrn.cancer.gov/data-and-resources/publications/17360030-1014-inverse-correlation-between-rassf1a-hypermethylation-kras-and-braf-mutations-in-cervical-adenocarcinoma/ Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical... This is a publication by a member of the Early Detection Research Network. inverse correlation https://profiles.wustl.edu/en/publications/association-of-braf-mutations-with-survival-and-recurrence-in-sur/fingerprints/?sortBy=alphabetically Association of BRAF mutations with survival and recurrence in surgically treated patients with... https://pubmed.ncbi.nlm.nih.gov/33778733/ Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with BRAF Mutation and 5-year... https://pubmed.ncbi.nlm.nih.gov/23441035/?dopt=Abstract&holding=idemdclib_fft&otool=idemdclib Reversible and tissue-specific activation of MAP kinase signaling by tamoxifen in Braf(V637)ER(T2)... Deregulated MAP kinase (MAPK) signaling plays key roles in developmental and adult disease processes, but the experimental activation of MAPK is a currently... https://pubmed.ncbi.nlm.nih.gov/26823846/ Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in... The V600E mutation in the B-type Raf kinase (BRAF) gene is a common genetic change in cases of papillary thyroid carcinoma (PTC) that appears to play a key... https://pmc.ncbi.nlm.nih.gov/articles/PMC7665856/ A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF... Tumors of the metastatic colorectal cancer (mCRC) patients that are wildtype (WT) for KRAS or NRAS mutations respond more favorably to anti-epidermal growth... https://pubmed.ncbi.nlm.nih.gov/29209533/ Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II... Despite encouraging preclinical data, our study did not show signs of clinical activity for vinorelbine in this patients' population. Further investigations on... metastatic colorectal cancer https://pubmed.ncbi.nlm.nih.gov/23725167/ BRAF mutations in Iranian patients with papillary thyroid carcinoma These findings support involvement of V600E mutations in PTC occurrence in Iran. Assessment of correlations between BRAF V600E mutations and papillary thyroid... braf mutations iranian patients thyroid https://pubmed.ncbi.nlm.nih.gov/40240371/ Targeting PLK1-CBX8-GPX4 axis overcomes BRAF/EGFR inhibitor resistance in BRAFV600E colorectal... https://impacts.ucar.edu/en/publications/associations-of-mc1r-genotype-and-patient-phenotypes-with-braf-an/ Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma -... https://www.ncbi.nlm.nih.gov/Structure/pdb/4YHT 4YHT: bRaf complexed with an inhibitor Serine/threonine-protein kinase B-raf3-[(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-N-methyl-4-(morpholin-4-yl)benzenesulfonamideGLYCEROL with an braf inhibitor https://pubmed.ncbi.nlm.nih.gov/24353068/ Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of... Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case... https://pharma.economictimes.indiatimes.com/news/pharma-industry/pfizer-pushing-braf-lung-cancer-mutation-testing-to-grow-market-for-braftovi/113345734 Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi, ETPharma The company presented three-year follow-up data from a Phase 2 study on Saturday looking at patients with BRAF V600E-mutant metastatic non-small cell lung... https://tobias-lib.ub.uni-tuebingen.de/xmlui/handle/10900/156215 Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF... https://pubmed.ncbi.nlm.nih.gov/39336897/ Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-azd6244-and-dacarbazine-advanced-melanoma-people-with-braf-gene-fault A trial of selumetinib with dacarbazine for advanced melanoma in people with a BRAF gene fault This trial looked at a drug called selumetinib alongside dacarbazine for people with melanoma that has spread to another part of the body. https://pubmed.ncbi.nlm.nih.gov/27382093/ BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to... In children with LCH, BRAF(V600E) mutation was associated with high-risk features, permanent injury, and poor short-term response to chemotherapy. Further... langerhans cell histiocytosis https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.986376/full Frontiers | Identification of novel natural drug candidates against BRAF mutated carcinoma; An... The BRAF gene is responsible for transferring signals from outside of the cell to inside of thenucleus by converting a protein namely B-Raf through the RAS/M... drug candidates https://pubmed.ncbi.nlm.nih.gov/22256804/?dopt=Abstract RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.... squamous cell carcinomas https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT01682083&r=1 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive... Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). https://pubchem.ncbi.nlm.nih.gov/bioassay/1746109 AID 1746109 - Inhibition of BRAF in human NCI-H929 cells at 10 uM by mass spectroscopic analysis... BioAssay record AID 1746109 submitted by ChEMBL: Inhibition of BRAF in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control. https://pure.psu.edu/en/publications/mast-cell-leukemia-with-novel-braf-variant-and-concomitant-atypic/ Mast cell leukemia with novel BRAF variant and concomitant atypical KIT variant - Penn State https://eprints.soton.ac.uk/501432/ Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice... raf inhibitors https://pubmed.ncbi.nlm.nih.gov/26541605/ Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH More than half of human colorectal cancers (CRCs) carry either KRAS or BRAF mutations and are often refractory to approved targeted therapies. We found that... https://pubmed.ncbi.nlm.nih.gov/25437182/ Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation Our exploratory study highlighted some factors that deserve to be further investigated in order to provide a framework for improving melanoma treatment... in silico https://pmc.ncbi.nlm.nih.gov/articles/PMC1959359/ The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer - PMC To examine the prevalence of BRAF mutation among thyroid cancer histologic subtypes and determine the association of BRAF mutation with indicators of poor... https://pubmed.ncbi.nlm.nih.gov/29271794/ BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and... The B-Raf proto-oncogene (BRAF) encodes a cytoplasmic serine/threonine kinase with a key role in regulating the mitogen-activated protein kinase signal... https://pubmed.ncbi.nlm.nih.gov/24933606/ Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma BRAF and MEK inhibitors are not established treatments for non-V600 mutation-positive metastatic melanoma. We carried out a retrospective analysis of efficacy... https://pubmed.ncbi.nlm.nih.gov/31672130/ Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E... Combined, our results support that inclusion of proteomics can predict drug response and identify co-therapies in a basket setting. https://pubchem.ncbi.nlm.nih.gov/bioassay/2051389 AID 2051389 - Selectivity interaction (KinomeScan (DiscoverX)) EUB0000699a BRAF - PubChem BioAssay record AID 2051389 submitted by ChEMBL: Selectivity interaction (KinomeScan (DiscoverX)) EUB0000699a BRAF. aid selectivity interaction discoverx braf https://boris-portal.unibe.ch/entities/publication/5caf3dde-cc4b-4c92-ad2e-a681e9276287 Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art... Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches... https://pubmed.ncbi.nlm.nih.gov/33738249/ Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients https://researchdiscovery.drexel.edu/esploro/outputs/graduate/Efficacy-of-next-generation-BRAF-inhibitors-in/991015327414504721 Efficacy of next-generation BRAF inhibitors in differentiated thyroid carcinomas - Drexel University The serine-threonine kinase BRAF is mutated in 50% of papillary thyroid carcinoma (PTC), the most common form of thyroid cancer. The vast majority of BRAF... next generation braf inhibitors https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2013.00281/full Frontiers | Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of ... colorectal cancer the role frontiers toward molecular https://pubmed.ncbi.nlm.nih.gov/16827748/ Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF... The molecular biology of metastatic potential in melanoma has been studied many times previously and changes in the expression of many genes have been linked... gene expression profiles https://researchconnect.buffalo.edu/en/publications/anti-ctla-4-and-braf-inhibition-in-patients-with-metastatic-melan/ Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases - SUNY... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1468233/full Frontiers | BRAF V600E-mutated lung adenocarcinoma with thyroid metastasis as the initial... Thyroid metastasis of lung adenocarcinoma is exceedingly uncommon. Here we present a case of a 72-year-old Chinese male with hoarseness, dysphagia, pain, and... https://researchconnect.buffalo.edu/en/publications/braf-inhibition-in-brafsupv600sup-mutant-gliomas-results-from-the/ BRAF inhibition in BRAFV600-mutant gliomas: Results from the VE-BASKET study - SUNY University at... https://www.wikidata.org/wiki/Q40572664 Microarray expression profiling in melanoma reveals a BRAF mutation signature. - Wikidata scientific article published on May 2004 microarray expression profiling melanoma https://openresearch-repository.anu.edu.au/items/0a0a63ec-eb86-4978-ac22-af57710ebc83 Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer Abstract Background: Resection of oligometastases improves survival in metastatic colorectal cancer (mCRC). It is unclear whether the benefit is consistent for...